$AFMD
Affimed N.V.
PRICE
$3 ▲6.762%
Last Close
VOLUME
448,288
DAY RANGE
2.75 - 3.03
52 WEEK
2.23 - 7.39
Key Metrics
Market Cap
370.26 M
Beta
1.42
Avg. Volume
1.23 M
Shares Outstanding
123.42 M
Yield
0%
Public Float
0
Next Earnings Date
2022-08-11
Next Dividend Date
Company Information
Affimed is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company's proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK platform predictably generates customized innate cell engager (ICE®) molecules, which use patients' immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE®. Headquartered in Heidelberg, Germany, with offices in New York, New York, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients' lives.
Website: www.affimed.com
HQ: ,
Related News